Log in

NASDAQ:CLLSCellectis Stock Price, Forecast & News

$18.65
+0.59 (+3.27 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.42
Now: $18.65
$18.99
50-Day Range
$13.70
MA: $18.00
$21.02
52-Week Range
$7.32
Now: $18.65
$21.97
Volume136,328 shs
Average Volume224,298 shs
Market Capitalization$792.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Read More
Cellectis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.99 million
Book Value$8.37 per share

Profitability

Net Income$-102,090,000.00

Miscellaneous

Employees161
Market Cap$792.07 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by COVID-19 (Coronavirus)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have increased by 63.2% and is now trading at $18.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cellectis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.06. The biotechnology company had revenue of $51.91 million for the quarter, compared to analyst estimates of $21.07 million. Cellectis had a negative net margin of 93.27% and a negative return on equity of 17.60%. View Cellectis' earnings history.

What price target have analysts set for CLLS?

7 Wall Street analysts have issued 1 year price targets for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' share price to reach $32.33 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price. View analysts' price targets for Cellectis.

Has Cellectis been receiving favorable news coverage?

Press coverage about CLLS stock has trended negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future. View the latest news about Cellectis.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 309,200 shares, a drop of 8.0% from the May 31st total of 336,000 shares. Based on an average trading volume of 195,100 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.7% of the shares of the stock are short sold. View Cellectis' Current Options Chain.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $18.65.

How big of a company is Cellectis?

Cellectis has a market capitalization of $792.07 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.